Sudah Shaheb, in Macy, NE - Internal Medicine

Sudah Shaheb, is a Internal Medicine - Endocrinology, Diabetes & Metabolism physician based in Macy, Nebraska. Sudah Shaheb is licensed to practice in Nebraska (license number 21038) and his current practice location is 100 Indian Drive, Macy, Nebraska. He can be reached at his office (for appointments etc.) via phone at (402) 878-2440.

NPI number for Sudah Shaheb is 1972712750 and his current mailing address is P.o. Box 706 Hwy 77/75, Winnebago Tribe Of Nebraska, Winnebago, Nebraska. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1972712750.

Contact Information

	Sudah Shaheb,
	100 Indian Drive, Macy, NE 68039
	(402) 878-2440
	(402) 878-2831

Physician's Profile

Full Name	Sudah Shaheb
Gender	Male
Speciality	Internal Medicine - Endocrinology, Diabetes & Metabolism
Location	100 Indian Drive, Macy, Nebraska
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1972712750
Provider Enumeration Date: 05/21/2007
Last Update Date: 10/24/2012

Medical Identifiers

Medical identifiers for Sudah Shaheb such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1972712750	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RE0101X	Internal Medicine - Endocrinology, Diabetes & Metabolism	21038 (Nebraska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sudah Shaheb is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sudah Shaheb, P.o. Box 706 Hwy 77/75, Winnebago Tribe Of Nebraska, Winnebago, NE 68071-0706 Ph: (402) 878-2440	Sudah Shaheb, 100 Indian Drive, Macy, NE 68039 Ph: (402) 878-2440

News Archive

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

Asuragen launches new miRNA Biofluids service offering

Asuragen, Inc. announced today the launch of its new miRNA Biofluids service offering designed to interrogate miRNAs from serum, plasma, cerebral spinal fluid, and urine. Supported by a growing body of literature, the utility of miRNA biomarkers in biofluids has been demonstrated for numerous disease areas including Cancer, Neurology, Autoimmune, and Cardiovascular diseases.

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

Researchers at the University of California, San Diego School of Medicine developed a method to expand the types of chromosomal abnormalities that noninvasive prenatal testing (NIPT) can detect. The study, published November 9 by Proceedings of the National Academy of Sciences, uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

Iron deficiency: an interview with Dr Thierry Teil

Iron deficiency is, in fact, one of the most common nutritional disorders. It affects between three and five billion people, which is between half and two-thirds of the world population (about seven billion). Iron deficiency anemia is a subset of iron deficiency, that is about two billion people according to the WHO...

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

Sudah Shaheb, - Internal Medicine in Macy, NE